MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
News May 14, 2014
MRC Technology announced it has established a drug discovery collaboration with global pharmaceutical company, Daiichi Sankyo. The agreement will focus on the identification and selection of novel drug targets with the potential to become potent and selective therapeutics including oncology, cardiovascular and metabolic diseases.
Under the terms of the agreement, MRC Technology will provide Daiichi Sankyo with details of potential drug targets sourced from academia. Daiichi Sankyo will have the opportunity to work with MRC Technology, who is responsible for screening followed by hit validation and future optimization of selected targets, as part of a collaborative project team. The project provides an ideal opportunity to combine the traditional strengths in drug discovery and development of Daiichi Sankyo with the rich knowledge of targets and disease biology available in academia provided by MRC Technology’s Centre for Therapeutics Discovery.
Justin Bryans, MRC Technology’s Director of Drug Discovery said, “Our aim is to translate early stage academic research into new therapeutic opportunities. Collaborating with Daiichi Sankyo early in this process means we can tap into their wealth of drug discovery experience with the view to generating novel chemical entities faster.”
The collaboration agreement was facilitated by MRC Technology’s agent in Japan, Summit Pharmaceuticals International (SPI).
Target information and financial terms of the agreement have not been disclosed.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE